Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 22

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 22
---
 should carefully consider the risks described under “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the SEC, and all other information contained in, or incorporated by reference in, this prospectus, as updated by those subsequent filings with the SEC under the Exchange Act, before making an investment decision. The risks and uncertainties described below and incorporated by reference are not the only ones we face. Additional risks and uncertainties not presently known to us may also adversely affect our business. Our business, financial condition and/or results of operations could be materially and adversely affected if any of these risks occur, and as a result the trading price of the Depositary Shares could decline and you could lose all or part of your investment.

This prospectus also contains forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors.

Risks Related to This Offering

We are selling a substantial number of Depositary Shares in this offering, which could cause the price of our Depositary Shares to decline.

In this offering, we are offering up to an aggregate of 3,377,110 Depositary Shares, Pre-Funded Warrants to purchase up to 3,377,100, and Series L Warrants exercisable for up to 3,377,110 Depositary Shares.

Additionally, under the
zero cash exercise price option of the Series L Warrants, during the period of 90 calendar days following the issue date of the Series
L Warrants, a holder of the Series L Warrant has the right to receive, without payment of any additional cash to the Company, an aggregate
number of Depositary Sharesequal to the product of (x) the aggregate number of Depositary Sharesthat would be issuable upon a cash exercise of the Series L Warrant and (y) two (2). The Series L Warrants also include
exercise price reset provisions, which could result in the issuance of a significantly higher number of shares upon exercise. At 4:01
p.m. Eastern time on the First Reset Date, the exercise price of the Series L Warrants will be reset to a price equal to the lower of
(i) the exercise price then in effect and (ii) the greater of (a) 80% of lowest VWAP during the period beginning on the 3rd trading day
after